Getting a testosterone level checked used to mean a doctor's office, a referral, and a wait. Now it can mean a ten-minute intake form on a phone screen. That shift is real and it has genuinely helped people who were putting off a conversation they needed to have. But a shorter path to a prescription raises an honest question that convenience alone cannot answer: is the medicine on the other end of that form being practiced the same way it would be in an endocrinologist's office, or a faster, thinner version of it?
There is an actual answer to that question, because testosterone therapy is one of the more thoroughly specified areas of medicine. A professional body has written down, in detail, what a correct diagnosis requires and what a correct treatment plan monitors for. That document is a guideline, and whether a program follows it, loosely follows it, or skips it, is something a patient can actually check.
What the guideline says has to happen before a prescription
The Endocrine Society's 2018 clinical practice guideline lays out the sequence. A diagnosis of hypogonadism should rest on two things together, not one: symptoms consistent with low testosterone, and concentrations that are unequivocally and consistently low. The word "consistently" is doing real work. The guideline calls for confirming a low reading by repeating the morning fasting total testosterone measurement, because the hormone swings enough hour to hour that a single number is not sufficient grounds for a diagnosis on its own.
The guideline is just as specific about who should not start therapy yet. It recommends against starting testosterone in men planning fertility in the near term, and lists a set of conditions, including a cardiovascular event within the previous six months, untreated severe sleep apnea, and an elevated hematocrit, that should pause the conversation rather than end it at a prescription. None of this is exotic. It is the ordinary, unglamorous texture of a careful diagnosis: confirm the number twice, ask the two or three questions that change the risk calculus, and only then write the prescription.
Even the "low" threshold itself is not a single settled number. The Endocrine Society's harmonized cutoff is 264 ng/dL, while the American Urological Association's guideline uses 300 ng/dL, and other professional bodies have proposed figures lower still. A patient who gets two different answers from two different programs is not necessarily getting a wrong answer from either one. They are seeing two guideline committees that drew the line in slightly different places, which is itself worth knowing before treating any single cutoff as gospel.
What a secret shopper found when the guideline met the real market
In 2022, a research team at Northwestern Medicine, led by urologist Joshua Dubin, tested how closely that guideline was actually being followed. They built a single, realistic patient profile: a 34-year-old man with hypogonadal symptoms, normal total and free testosterone levels, and an explicit, stated desire to have children in the future, a scenario the guideline treats as a reason to hold off on testosterone therapy altogether, since the hormone can suppress sperm production. The team, posing as that patient, ran the same intake process through seven direct-to-consumer platforms operating across all fifty states.
The results, published in JAMA Internal Medicine, were not close. Despite the shopper's normal hormone levels and stated fertility plans, 85.7 percent of the platforms still offered testosterone therapy. Only one of the seven asked about recent cardiovascular events or future fertility at all, the two questions the guideline treats as gating criteria before treatment begins. The diagnostic thresholds the platforms actually used were scattered rather than standardized: one would only treat a total testosterone below 450 ng/dL, well under the guideline's own cutoffs, while the other six had no stated threshold whatsoever. The researchers were careful to note this is a young and fast-moving field with real upside for access; their concern was narrower and more specific, that the platforms they tested were not yet practicing medicine the way the guideline describes it.
Following the guideline and charging a fair price are two separate questions
A second, smaller study complicates the picture in a useful way. Researchers compared the evaluation and treatment practices of several direct-to-consumer telemedicine platforms against American Urological Association guidelines, alongside a cost comparison against a traditional tertiary care center. That study found the platforms it examined were largely following practice guidelines, the opposite emphasis from the Dubin study, but that ongoing treatment through those platforms carried a meaningfully higher cost than equivalent care at a center that could bill insurance.
Read together, the two studies make the same point from different directions: guideline adherence and price are independent variables. A program can be inexpensive and still skip the steps that matter. A program can follow every step correctly and still be the costlier option for a given patient's insurance situation. Neither fact can be inferred from the other, which means both have to be checked on their own terms rather than assumed from a program's marketing or its price tag.
A short list worth bringing to any hormone conversation
None of this requires a medical degree to check. It requires knowing which four or five questions the guideline treats as load-bearing, and asking them directly.
Did the diagnosis rest on one blood draw or two confirmed low morning readings alongside symptoms, the standard the guideline actually specifies. Was the conversation about future fertility plans and recent cardiovascular history, had before a prescription was offered, not folded into fine print afterward. Is there a defined monitoring plan once treatment starts, including a baseline hematocrit and a prostate-risk conversation somewhere in the first year, rather than a one-time transaction. Is a named, board-certified physician reviewing the chart, not only an intake algorithm. And is the full ongoing cost, not just the introductory visit, stated plainly before anyone commits.
The same underlying logic travels well beyond testosterone. Whatever hormone is on the table, a diagnosis built on more than a single number, and a prescription that opens a monitoring relationship instead of closing a transaction, is the plain-language version of what "guideline-concordant" is actually trying to protect.
Common questions
Does being a direct-to-consumer, telehealth-based program automatically mean lower-quality hormone care?
Not according to the evidence itself. The cost-comparison study found platforms largely following AUA guidelines on the evaluation side, while charging more for ongoing treatment, and the Dubin study's criticism was aimed at specific gaps in specific platforms' intake process rather than the telehealth model as a category. The delivery channel is not the determining factor; whether a given program actually asks the gating questions and sets up real monitoring is.
Why do fertility plans and cardiovascular history matter so much before starting testosterone therapy specifically?
Testosterone therapy can suppress the body's own sperm production, which is why the Endocrine Society guideline recommends against starting it in men planning fertility in the near term. Cardiovascular history matters because the guideline's contraindication list includes a heart attack or stroke within the previous six months, a window during which the added physiological load of hormone therapy is considered an unnecessary risk. In the 2022 secret-shopper study, only one of seven platforms tested asked about either factor before offering treatment.
What does a guideline-concordant diagnosis actually require before any prescription?
Per the Endocrine Society's 2018 guideline, a diagnosis should combine symptoms and signs consistent with low testosterone with testosterone concentrations confirmed as low on a repeated morning fasting measurement, not a single test result taken on its own.
How does a monitoring plan after starting testosterone therapy typically work?
The guideline calls for evaluating the patient after treatment begins to check response and any adverse effects, alongside hematocrit monitoring and a prostate-cancer-risk conversation during the first year of treatment. The exact cadence is a matter for a treating physician to set and explain, but the underlying principle is that treatment opens an ongoing monitoring relationship rather than concluding at the prescription.
Why do different guidelines list different testosterone thresholds for a low diagnosis?
The Endocrine Society's harmonized reference threshold is 264 ng/dL, while the American Urological Association's guideline uses 300 ng/dL, with other professional bodies proposing other figures. The difference reflects how each committee weighed the underlying population data and assay standardization, not a disagreement about whether low testosterone is a real, treatable condition.
